Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KIF11 | P52732 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31315637 | 1.00 | GAA (0.57) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL436804 | 0.85 | GAA (0.59) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL29404322 | 0.85 | GAA (0.59) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL1149036 | 0.84 | TSHR (0.46) | GAATSHRGLAPOLBALDH1A1 | |
| SCHEMBL10357262 | 0.84 | TSHR (0.53) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL22607198 | 0.83 | GAA (0.69) | GAATSHRGLAPOLBKIF11 | |
| Hydrochloric Acid SCHEMBL8863493 | 0.83 | GAA (0.57) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL9367414 | 0.83 | GAA (0.40) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL11142948 | 0.82 | GAA (0.52) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL22606816 | 0.82 | GAA (0.67) | GAATSHRGLAPOLBKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129023-B1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EICOSIS LLC (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3129023-B1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EICOSIS LLC (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3131893-B1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| US-10377744-B2 | Potent soluble epdxide hydrolase inhibitors | EICOSIS, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377744-B2 | Potent soluble epdxide hydrolase inhibitors | EICOSIS, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20170174665-A1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EICOSIS, LLC | 2017-06-22 | — | — | US | disclosed |
| US-20170174665-A1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EICOSIS, LLC | 2017-06-22 | — | — | US | disclosed |
| EP-3129023-A1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Eicosis, LLC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20160108025-A1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG | 2016-04-21 | — | — | US | disclosed |
| US-20160108025-A1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG | 2016-04-21 | — | — | US | disclosed |
| CN-1234695-C | N-alkoxyalkyl-substituted benzimidazoles and use thereof as active agent aginst parasitic protozoans | BAYER AG (DE) | 2006-01-04 | — | — | CN | disclosed |
| EP-1326845-B1 | N-ALKOXYALKYL-SUBSTITUTED BENZIMIDAZOLES AND THE USE THEREOF AS AN AGENT AGAINST PARASITIC PROTOZOANS | BAYER HEALTHCARE AG (DE) | 2005-12-14 | — | — | EP | disclosed |
| US-20040044055-A1 | N-alkoxlyalkyl-substituted benzimidazoles and the use thereof as an agent against parastic protozoans | BAYER AKTIENGESELLSCHAFT (DE) | 2004-03-04 | — | — | US | disclosed |
| CN-1479725-A | N-alkoxyalkyl-substituted benzimidazoles and use thereof as active agent aginst parasitic protozoans | — | 2004-03-03 | — | — | CN | disclosed |
| EP-1326845-A1 | N-ALKOXYALKYL-SUBSTITUTED BENZIMIDAZOLES AND THE USE THEREOF AS AN AGENT AGAINST PARASITIC PROTOZOANS | Bayer Aktiengesellschaft (DE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030909-A1 | N-ALKOXYALKYL-SUBSTITUTED BENZIMIDAZOLES AND THE USE THEREOF AS AN AGENT AGAINST PARASITIC PROTOZOANS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-18 | — | — | WO | disclosed |
| US-4960539-A | Use of fluoromethylphenols as solvents for LC-polymers, and new fluoromethylphenols | BAYER AKTIENGESELLSCHAFT (DE) | 1990-10-02 | — | — | US | disclosed |
| EP-0286953-B1 | USE OF FLUOROMETHYL PHENOLS AS SOLVENTS FOR LC POLYMERS, AND FLUOROMETHYL PHENOLS | BAYER AG (DE) | 1990-09-26 | — | — | EP | disclosed |
| EP-0286953-A1 | Use of fluoromethyl phenols as solvents for LC polymers, and fluoromethyl phenols | BAYER AG (DE) | 1988-10-19 | — | — | EP | disclosed |
| EP-0180818-A2 | Benzoyl ureas and intermediates | BAYER AG (DE) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044055-A1 | N-alkoxlyalkyl-substituted benzimidazoles and the use thereof as an agent against parastic protozoans | PIGO, EPX, PIGK | GAA 995/4885TSHR 3153/4885GLA 3064/4885 |
| US-10377744-B2 | Potent soluble epdxide hydrolase inhibitors | EPHX1, EPHX2, LTA4H | GAA 2237/4885TSHR 4427/4885GLA 3279/4885 |
| US-20160108025-A1 | POLYCYCLIC HERG ACTIVATORS | KCNH3, KCNH2, KCNJ11 | GAA 924/4885TSHR 790/4885GLA 3281/4885 |
| US-20170174665-A1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, LTA4H | GAA 1917/4885TSHR 4673/4885GLA 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.